Indivior | 10-Q: Quarterly report
Indivior Announces New Study Highlighting Monthly SUBLOCADE As Potential Treatment Option For Opioid Use Disorder During and After Pregnancy
Indivior PLC Announces Total Voting Rights and Share Capital Update
Indivior PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $13
Indivior Non-GAAP EPS of $0.41 Beats by $0.17, Revenue of $266M Beats by $23.7M
Indivior Faces Revenue Challenges Amid Competitive Pressures
Stifel Maintains Indivior(INDV.US) With Buy Rating, Raises Target Price to $14.64
Indivior | 8-K: Indivior Announces Results for the First Quarter Ended March 31, 2025; FY 2025 Guidance Unchanged
Indivior's Growth Potential and Resilience Amid Market Challenges: A Buy Recommendation
Earnings Call Summary | Indivior(INDV.US) Q1 2025 Earnings Conference
Indivior Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Express News | Indivior Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results
Indivior Logs Lower Q1 Net Income, Revenue
Indivior Reaffirms 2025 Guidance: Expects Net Revenue Of $995M-$1.025B Vs. $1.046B Est.; Sees Adj. Gross Profit Of $185M-$225M
Earnings Flash (INDV.L) INDIVIOR Posts Q1 EPS $0.38
Indivior Q1 Adj. EPS $0.41 Beats $0.24 Estimate, Sales $266.00M Beat $262.35M Estimate
Press Release: Indivior Announces Q1 2025 Financial Results
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Indivior (INDV) Receives a Buy From Craig-Hallum